Recent News for RDY - Dr. Reddy's Laboratories Ltd

Date Title
Apr 21 Here’s What Hedge Funds Think About Dr. Reddy’s Laboratories Limited (RDY)
Apr 17 DOJ charges 31 docs for over-prescribing opioids
Apr 17 Dr. Reddy's to Release Q4 and Full Year FY 19 Results on May 17, 2019
Apr 16 Lannett down 4% on cautious SA article on alleged price collusion
Apr 15 Dr. Reddy's (RDY) Inks Deal to Acquire Portfolio of 42 ANDAs
Apr 15 Dr. Reddy's Lab acquires ANDA portfolio
Apr 13 Dr. Reddy's Laboratories Announces Acquisition of ANDA Portfolio
Apr 3 The Daily Biotech Pulse: Advaxis Offering, Roche's Spark Tender Offer Extended, Ascendis Earnings
Apr 2 Is India's 7.3% Growth Worth An Investment?
Apr 2 Promius Pharma, LLC. (a Wholly Owned Subsidiary of Dr. Reddy’s Laboratories Ltd.) Announces the Sale and Assignment of the US Rights for Its Marketed Dermatology Brands to Encore Dermatology
Apr 1 Supernus' ADHD Candidate Positive in 4th Phase III Study
Mar 28 FDA's Gottlieb proposes higher standard for future opioid approvals
Mar 28 Falling Earnings Estimates Signal Weakness Ahead for Mylan (MYL)
Mar 26 Purdue Pharma settles opioid case in OK for $270M
Mar 21 The Daily Biotech Pulse: Biogen Plummets, FDA Greenlights Sleep Disorder Drug, Cellular Biomedicine Offering
Mar 20 Top Ranked Momentum Stocks to Buy for March 20th
Mar 11 FDA seeks $643M funding increase aimed at key initiatives
Mar 11 Canada to institute tighter restrictions on opioid marketing
Mar 4 Painkiller stocks in the red on possible Purdue bankruptcy
Mar 1 Factors of Influence in 2019, Key Indicators and Opportunity within Vanda Pharmaceuticals, Range Resources, Fortune Brands Home & Security, Dr. Reddy's Laboratories, BWX Technologies, and K12 — New Research Emphasizes Economic Growth
Feb 27 Watching for Signs of Global Risk Events
Feb 20 Dr. Reddy's relaunches generic Suboxone
Feb 20 Dr. Reddy's Laboratories Announces the Re-Launch of Its Buprenorphine and Naloxone Sublingual Film after Favorable Ruling in Patent Litigation
Feb 19 Maryland strikes out in reviving drug price-gouging law
Feb 15 FDA creates new accelerated review pathway for generic drug applications

Back to the Main RDY Page...